The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
4046241
mRNA drugs production from very small to very large-scale capacity: when to use batch versus continuous strategies
Date
March 21, 2024
Explore related products in the following collection:
The modern industrial biomanufacturing can be divided into three main principles: batch, fed-batch, and continuous processes. While continuous manufacturing processes are a standard in the chemical and petrochemical industries, biological and pharmaceutical sectors largely adopt batch mode manufacturing, due to its easier and more flexible process optimization at early stages of product development. At Univercells, we are designing and developing innovative biomanufacturing technologies with a strong focus on enhancing accessibility through greater affordability, scalability and flexibility.
Consequently, the development of a sequential-staggered process enables us to combine the advantage of batch mode for process development while unlocking the same benefits as continuous mode for production. This approach has been translated into NtensifyTM, an all-in-one, simplified and integrated solution tailored to deliver today and tomorrow a wide range of production capacities, ultimately contributing to global deployment for underserved populations.
As we consider the evolving needs of people living in low-and-middle income countries (LMICs), we need to re-think how we can help them meet their health goals. To do so, we need to consider the entire system from drug development through supply…
Cell culture media and process are the key influence factor in the manufacturing cost of biotherapeutics. OPM has developed a new generation chemically-defined CHO media that are proved to work with a variety of CHO clones, like CHO-DG44, CHO-K1, CHO ZN and CHO-S, etc…
The pandemic helped to highlight the inequitable access to vaccines that exists for patients in underserved communities worldwide based on both local resources and community location…
Local biomanufacturing capacity could transform access to therapeutics in low- and middle-income countries (LMICs) by promoting self-sufficiency to address current and future needs for biologic drugs and vaccines, ultimately improving both regional livelihoods and health outcomes…